Charles River Laboratories and WuXi PharmaTech, Inc. have decided to terminate their previously announced acquisition agreement. Under the termination agreement, Charles River will pay WuXi a $30 million breakup fee for full satisfaction of the parties’ obligations under the acquisition agreement. Charles River also announced that its board of directors has authorized a new $500 million stock repurchase program. James C. Foster, chairman, president and chief executive officer said, “We believ...